Clinical trial
Study Evaluating Effexor XR for Major Depression.
NCT00225511 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00225511 |
|---|---|
| Title | Study Evaluating Effexor XR for Major Depression. |
| Official title | Phase III Multi-Center, Double-Blind, Comparative Study of Effexor XR for the Treatment of Depression |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Depression |
| Intervention type | Drug |
| Interventions | Effexor XR, Milnacipran |
| Enrollment | 590 |
| Start date | Jun 1, 2004 |
| First posted | Sep 23, 2005 |
| Last update posted | May 24, 2007 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: